Navigation Links
NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System

MAPLE GROVE, Minn., April 5, 2011 /PRNewswire/ -- NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device (HDE) for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat.  The HDE allows for the treatment of up to 4,000 patients per year in the U.S.


Christopher Dowd, M.D., Clinical Professor of Neuro-Interventional Radiology at the University of California at San Francisco and Medical Director for NeuroVasx, Inc., said, "The large, giant and wide-neck cerebral aneurysm population continues to remain the most challenging to treat.  cPAX will offer physicians an alternative solution that we believe can make a significant impact in treatment and outcome for these patients."  Ricardo Hanel, M.D., PhD, Associate Professor of Neurosurgery at the Mayo Clinic in Jacksonville, Florida and Co-Principal Investigator in the cPAX Clinical Trial, states, "The longer term stability we have seen in the clinical studies using cPAX in larger aneurysms gives me great confidence in the positive impact this product will have on the care of our patients."

A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain which can be caused by a number of factors including congenital defects, high blood pressure, atherosclerosis, cancer, drug use or head trauma.  If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke, or bleeding on the brain.  According to the National Institutes of Health, approximately 40% of these patients do not survive the first 24 hours.  The worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually, approximately 200,000 of which may be treatable with intracranial surgery using minimally invasive techniques.  

cPAX is a polymeric strand delivered into the aneurysm using a technique similar to currently available platinum coil technologies.  cPAX, because of its soft polymeric material, is designed to achieve more complete filling of the aneurysm with the probable benefit of greater long term stability.  A significant feature of cPAX in comparison to currently available technologies is that it offers the physician the ability to detach the device at any point versus a fixed detachment zone common in platinum coils.  The polymeric material also allows for non-invasive CT and MRI scans with little or no artifact for more accurate patient follow-up assessment.

Eric B. Timko, President and CEO of NeuroVasx, said, "This FDA approval brings an important cutting-edge technology to a patient population that is currently underserved.  We are excited to offer this treatment to patients and we look forward to working with our key physicians to bring this product to market."

About NeuroVasx, Inc.

NeuroVasx, Inc. ( is a privately held medical device company located in Maple Grove, MN. The company is dedicated to the development and commercialization of technologies for the minimally invasive treatment of hemorrhagic and ischemic stroke.  The worldwide market potential for stroke treatment devices is estimated to be over $3 billion.

SOURCE NeuroVasx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
2. superDimension Receives FDA 510(k) Clearance for Marker Delivery Kit
3. Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
4. Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication
5. Senate Receives Rx Blueprint Plan That Reduces Spending and Increases Quality
6. CarePoint Partners Receives Louisiana Dietetic Association Corporate Award
7. Adeonas Multiple Sclerosis Trial Receives $409,426 Grant
8. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
9. Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System
10. Qualitest Receives FDA Approval for Toresmide Tablets (Generic Demadex®) 5 mg, 10 mg, 20 mg, 100 mg, for the Treatment of Edema Associated with Congestive Heart Failure, Renal Disease, or Hepatic Disease
11. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
Post Your Comments:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):